Friday 30 October 2026 · Edition of the day

Current editionPast editions →

The Skeptic's Daily

The day's biggest stories, taken apart. For each one: what is actually established, what is only asserted, the questions worth asking — and a plausibility score for the central claim, given everything currently known.

Stories
1
Average plausibility
91%
How to read the score
It rates how well the core claim is evidenced — not how important the story is, nor whether it is good or bad news.
01HealthNorth America

RFK Jr. plans wider access to unapproved peptides

Several newsrooms report a policy to ease access through compounding pharmacies, but the excerpts leave its start date and the drugs’ safety evidence unresolved.

Health Secretary Robert F. Kennedy Jr. has moved to expand access to six peptides that lack FDA approval, according to BBC, CBS and other reporting. BioPharma Dive reports that HHS plans not to take enforcement action against certain providers preparing the drugs. NBC says pharmacies can offer them immediately, while Associated Press reporting describes a draft awaiting comments before finalization. Health experts and FDA scientists have raised concerns about inadequate clinical testing.

What holds up

  • ✓CBS, The Washington Post and BioPharma Dive agree that the policy covers six unapproved peptides. Their accounts largely describe the same government policy, rather than separately proving its effects on access.
  • ✓BioPharma Dive and NBC describe a pause in enforcement against providers preparing these drugs. That is not FDA approval or evidence that the drugs work.
  • ✓BBC reports expert warnings, and KFF Health News adds that FDA scientists warned in July that the drugs had not been adequately vetted in clinical trials.

What doesn't yet

  • ?The timing remains unclear: NBC says pharmacies can start offering the peptides now, while AP says the government will take comments for two weeks before finalizing the measure. The excerpts do not explain how those timelines fit together.
  • ?Kennedy says limited preparation by pharmacies under safeguards offers a more controlled alternative. The supplied evidence does not establish that benefit, and AP reports that FDA scientists opposed the change, citing six people familiar with its development.
  • ?BBC’s wording about a lack of human trials is broader than KFF’s description of inadequate testing. These excerpts do not provide trial records for each peptide or full-article verification; AP copies across websites also represent one reporting effort, not separate confirmations.

Ask before you share

  • →When does the enforcement pause take effect, and which providers and safeguards does it cover?
  • →What human studies exist for each of the six peptides, and what do they show about benefits, side effects and long-term risks?
  • →Has HHS published evidence supporting Kennedy’s claim that this route offers patients a more controlled alternative?

Sources & original reporting

  1. [1]BBC News · Published 29 Oct 2026 · bbc.co.uk
  2. [2]CBS News · Published 28 Oct 2026 · cbsnews.com
  3. [3]The Washington Post · Published 28 Oct 2026 · washingtonpost.com
  4. [4]Biopharmadive · Published 29 Oct 2026 · biopharmadive.com
  5. [5]NBC News · Published 28 Oct 2026 · nbcnews.com
  6. [6]Record Eagle · Published 28 Oct 2026 · record-eagle.com
  7. [7]Kffhealthnews · Published 29 Oct 2026 · kffhealthnews.org